ST. LOUIS, Feb. 22 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is public health, announced today that the Company’s first sickle cell patient had her pain go away after starting GenoMed’s trial.
The patient is a middle-aged African American woman who for years has required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed’s trial on Dec. 22, 2005, she experienced no pain until her trial medication ran out on February 6, 2006. This is what her physician wrote:
“That patient with SS [hemoglobin SS, or sickle cell disease] and a significant daily requirement for Vicodin...and the occ. [occasional] im [intramuscular] Demerol, was discharged a few weeks ago (12/22 to be exact) on [GenoMed’s protocol, which uses a blood pressure medication] at night. I tested the effect on her blood pressure during that hospitalization. BP went down, but not too far.
“Today she tells me she has pain again and wants some more Vicodin. However, I now discover that she failed to renew her ... prescription [for GenoMed’s protocol] when the first one ran out. So, it appears she went for approximately 30 days, requiring no Vicodin, on just [GenoMed’s protocol] alone.
“She’ll start back on [GenoMed’s protocol] now, and I asked her to give it 4 days before using any Vicodin ...
“She continues on hydroxyurea, Plavix, and Lovenox b.i.d because of the hypercoagulability [excess tendency for blood to clot]. The hydroxurea raised her %Hgb F [hemoglobin F for ‘fetal'; a non-sickling form of hemoglobin] well and this is holding, but this is the first time the pain has been controlled off Vicodin.
“Prior to this experiment, for over two years, there has not been more than a day, at least during the winter mos., when she has not required some Vicodin.”
Said Dr. David Moskowitz, GenoMed’s CEO and Chief Medical Officer, “This case report is extremely promising, since it’s very hard to make the pain in sickle cell disease go away. There’s no placebo effect in sickle cell disease. Of course, we need to see if our protocol continues to work in this patient, as well as in more patients. But ours could be one of the least toxic and more effective treatments for sickle cell disease yet.”
About GenoMed
GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including sickle cell disease. To enroll in GenoMed’s trial, please contact Dr. Moskowitz at dwmoskowitz@genomed.com .
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed
CONTACT: David W. Moskowitz MD, CEO of GenoMed, +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomed.com/
